🔎 Trials Near Me

Início › Câncer Endometrial › Washington

Ensaios clínicos de Câncer Endometrial em Washington

20 estudos para Câncer Endometrial estão buscando participantes em locais em Washington.

Cidades em Washington

Texto oficial do estudo (Inglês)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Providence Regional Cancer System-Lacey, Lacey
  • e mais 4
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Washington, Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
  • e mais 1
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT07198074

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 28 de set. de 2026 · NCT05112601

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT04590326

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • Swedish Medical Center First Hill, Seattle
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT05640999

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • University of Washington Fred Hutchinson, Seattle
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • USOR - NW Cancer Specs P.C., Vancouver
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 9 de set. de 2026 · NCT07166094

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Swedish Cancer Center, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 21 de ago. de 2026 · NCT05548296

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Swedish Cancer Institute, Seattle
  • Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04104776

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT07444814

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Wenatchee Valley Hospital and Clinics, Wenatchee
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Swedish Cancer Institute, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Kennewick
  • Research Site, Seattle
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 29 de jul. de 2026 · NCT07044336

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
  • Summit Cancer Centers, Spokane
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT05377996

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT06993844

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  • Medical Oncology Associates, Spokane
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de jun. de 2026 · NCT07503808

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT06395519

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

  • Swedish Cancer Institute, Seattle
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de nov. de 2025 · NCT05997017

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Seattle
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.